Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies

Sarah Conway; Cory Dodson; Gavin Hui; C William Pike; Kristin Galetta

doi:10.1016/j.msard.2024.105921

Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies

Mult Scler Relat Disord. 2024 Oct 17:92:105921. doi: 10.1016/j.msard.2024.105921. Online ahead of print.

Authors

Sarah Conway¹, Cory Dodson², Gavin Hui³, C William Pike³, Kristin Galetta⁴

Affiliations

¹ Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
² Department of Neurology, Stanford University, Palo Alto, CA, USA.
³ Atropos Health, New York, NY, USA.
⁴ Department of Neurology, Stanford University, Palo Alto, CA, USA. Electronic address: kgaletta@stanford.edu.

PMID: 39454471
DOI: 10.1016/j.msard.2024.105921

Abstract

This study investigates the occurrence of inflammatory vaginitis in women with Multiple Sclerosis (wwMS) undergoing B-cell depleting therapy versus other disease-modifying therapies (DMTs). Retrospective analysis of medical records from Stanford University between 2015-2023 shows similar rates of vaginitis in both groups, suggesting no significant association with B-cell therapy. Despite this, inflammatory vaginitis remains prevalent in both treatment groups, warranting further investigation into its mechanisms and management.

Publication types

Letter